acut
reject
host
respons
recognit
graft
foreign
occur
day
month
even
year
transplant
reject
divid
cellular
humor
form
acut
cellular
reject
predomin
type
acut
reject
lung
allograft
mediat
lymphocyt
recogn
foreign
human
leukocyt
antigen
hla
antigen
humor
reject
mediat
preform
de
novo
recipi
antibodi
therefor
also
refer
antibodymedi
reject
amr
antigen
donor
organ
cell
acut
reject
import
complic
patient
lung
allograft
twentynin
percent
adult
patient
least
one
episod
treat
acut
reject
discharg
hospit
year
transplant
moreov
death
occur
within
first
day
day
year
follow
lung
transplant
due
acut
reject
respect
addit
frequenc
sever
acut
reject
thought
repres
major
risk
factor
subsequ
develop
bronchiol
obliteran
syndrom
bo
hla
mismatch
genet
recipi
factor
type
immunosuppress
vitamin
defici
infect
risk
factor
acut
reject
instanc
recipi
alloimmun
respons
thought
relat
recognit
differ
donor
antigen
lead
acut
lung
allograft
reject
inde
higher
degre
hla
mismatch
shown
increas
risk
acut
reject
although
effect
consist
across
hla
loci
studi
mismatch
hladr
hlab
hlaa
loci
well
combin
three
loci
appear
specif
import
instanc
acut
reject
within
month
transplant
shown
associ
hladr
mismatch
acut
reject
year
found
associ
hlab
mismatch
sever
host
genet
characterist
studi
may
modul
acut
lung
reject
instanc
genotyp
lead
increas
may
protect
acut
reject
multidrugresist
genotyp
appear
predispos
persist
acut
reject
resist
immunosuppress
treatment
incid
acut
reject
appear
agedepend
lowest
incid
acut
reject
infant
age
howev
children
higher
risk
acut
reject
adult
furthermor
registri
intern
societi
heart
lung
transplant
ishlt
show
incid
acut
reject
discharg
followup
slightli
higher
younger
adult
lung
allograft
recipi
age
year
compar
entir
adult
popul
least
one
acut
reject
episod
incid
acut
reject
seem
chang
older
lung
transplant
recipi
age
higher
regimen
immunosuppress
might
also
play
role
acut
reject
instanc
rate
acut
reject
first
year
transplant
highest
among
recipi
cyclosporinebas
regimen
lowest
among
tacrolimusbas
regimen
vitamin
defici
might
also
play
role
acut
reject
studi
found
lung
recipi
oh
defici
around
time
transplant
vitamin
ddefici
recipi
episod
acut
cellular
reject
infect
similar
associ
vitamin
defici
acut
reject
describ
solid
organ
recipi
includ
liver
kidney
heart
although
exact
mechan
phenomenon
entir
clear
specul
vitamin
might
slow
matur
antigenpres
cell
vitro
studi
shown
vitamin
might
induc
dendrit
cell
acquir
toler
andor
synergist
effect
vitamin
analog
immunosuppress
occur
viral
infect
also
thought
modul
immun
system
increas
alloreact
inde
high
incid
acut
reject
found
lung
transplant
recipi
communityacquir
respiratori
tract
infect
human
influenza
viru
respiratori
syncyti
viru
rhinoviru
coronaviru
parainfluenza
viru
chlamydia
pneumonia
infect
also
link
develop
acut
reject
one
studi
signific
cmv
infect
impact
cmv
prophylaxi
strategi
acut
reject
frequenc
clear
time
clinic
cours
acut
reject
variabl
acut
reject
often
identifi
surveil
transbronchi
biopsi
asymptomat
patient
symptom
occur
might
nonspecif
overlap
seen
complic
diseas
patient
popul
symptom
might
includ
dyspnea
fever
leukocytosi
widen
alveolararteri
oxygen
gradient
highergrad
reject
appear
caus
sever
symptom
lead
acut
respiratori
distress
patient
reject
pulmonari
function
test
may
show
decreas
forc
expiratori
volum
fev
vital
capac
vc
although
spirometri
sensit
greater
detect
infect
reject
grade
higher
differenti
two
furthermor
use
spirometri
diminish
singl
lung
transplant
recipi
dysfunct
nativ
lung
confound
pulmonari
function
test
result
although
approxim
half
case
acut
reject
chest
xray
studi
normal
illdefin
perihilar
lower
lobe
opac
along
septal
line
pleural
effus
may
seen
find
ct
scan
might
includ
groundglass
opac
septal
thicken
volum
loss
nodul
consolid
pleural
effus
infiltr
observ
imag
studi
first
week
lung
transplant
usual
caus
reimplant
respons
ie
reperfus
edema
factor
infiltr
persist
beyond
first
week
follow
transplant
suggest
acut
reject
infect
howev
although
earli
author
small
studi
attempt
demonstr
use
chest
xray
chest
ct
scan
diagnosi
reject
recent
data
show
low
sensit
acut
reject
low
discriminatori
valu
reject
process
exhal
nitric
oxid
also
serv
marker
lung
injuri
often
increas
patient
lymphocyt
bronchiol
acut
reject
furthermor
studi
inert
ga
singlebreath
washout
slope
alveolar
plateau
helium
sensit
acut
reject
although
present
patient
sever
ancillari
studi
may
suggest
presenc
acut
allograft
reject
none
find
specif
therefor
tissu
diagnosi
necessari
definit
diagnosi
histopatholog
adequ
lung
biopsi
sampl
obtain
transbronchi
biopsi
current
gold
standard
assess
lung
allograft
reject
distinguish
reject
clinic
mimick
aspir
infect
drug
toxic
recurr
diseas
recent
transbronchi
cryobiopsi
techniqu
introduc
yield
larger
biopsi
contain
alveoli
small
airway
vein
venul
exhibit
less
procedur
alveolar
hemorrhag
crush
artifact
convent
forcep
transbronchi
allograft
biopsi
although
cryobiopsi
appear
safe
forcep
biopsi
complic
occur
one
reason
techniqu
far
univers
perform
purpos
lung
tissu
specimen
lung
allograft
includ
wedg
biopsi
explant
retranspl
autopsi
specimen
lung
transplant
recipi
wedg
biopsi
although
seldom
obtain
clinic
practic
specimen
explant
provid
use
histopatholog
insight
etiolog
lung
allograft
dysfunct
advanc
stage
follow
possibl
medic
intervent
cellular
alloreact
injuri
donor
lung
affect
vasculatur
airway
perivascular
mononuclear
cell
infiltr
hallmark
acut
cellular
reject
infiltr
may
accompani
subendotheli
chronic
inflamm
eg
endotheli
intim
also
lymphocyt
bronchiol
characterist
small
airway
reject
histolog
chang
divid
grade
base
intens
cellular
infiltr
occurr
accompani
acut
lung
injuri
pattern
ishlt
sponsor
lung
reject
studi
group
lrsg
workshop
develop
work
formul
diagnosi
lung
reject
transbronchi
biopsi
sinc
grade
scheme
revis
twice
grade
scheme
strictli
patholog
base
morpholog
featur
recogn
transbronchi
biopsi
allograft
clinic
paramet
consid
due
overlap
histolog
featur
acut
reject
infect
grade
scheme
reli
absenc
concurr
infect
furthermor
infect
reject
may
occur
togeth
therefor
lrsg
recommend
grade
reject
rigor
exclus
infect
recent
classif
lung
allograft
biopsi
ishlt
consensu
classif
allograft
reject
tabl
attempt
made
accur
distinguish
grade
reject
sinc
treatment
larg
depend
histolog
grade
assess
experienc
pulmonari
pathologist
familiar
histopatholog
featur
criteria
use
grade
howev
interand
intraobserv
variabl
grade
impact
treatment
outcom
two
studi
use
grade
system
found
rel
good
interobserv
agreement
grade
kappa
howev
result
could
replic
anoth
studi
kappa
spite
dichotom
grade
versu
intraobserv
agreement
acut
reject
found
good
kappa
valu
use
revis
ishlt
classif
bhorad
colleagu
show
overal
concord
rate
grade
grade
b
specimen
site
pathologist
central
pathologist
howev
weight
kappa
score
studi
show
fair
moder
agreement
grade
kappa
valu
vari
less
chanc
agreement
moder
agreement
b
grade
kappa
valu
vari
interestingli
kappa
valu
b
grade
depend
time
elaps
transplant
biopsi
best
agreement
occur
biopsi
taken
within
week
transplant
slightli
higher
agreement
b
grade
respect
shown
studi
evalu
interobserv
agreement
two
transplant
pathologist
institut
use
revis
grade
scheme
although
cryobiopsi
larger
appear
easier
interpret
interobserv
reproduc
improv
use
cryobiopsi
studi
acut
reject
defin
presenc
perivascular
mononuclear
cell
infiltr
without
endotheli
progress
infiltr
becom
widespread
extend
alveolar
septa
subsequ
alveoli
major
mononuclear
cell
acut
reject
cell
although
studi
describ
increas
popul
b
cell
eosinophil
histolog
featur
reject
summar
tabl
featur
acut
cellular
reject
lack
although
biopsi
may
entir
normal
scatter
infrequ
blood
vessel
particularli
venul
alveol
lung
parenchyma
surround
rel
thin
ring
two
three
layer
chronic
mononuclear
cell
infiltr
fig
b
lymphocyt
rim
loos
compact
gener
circumferenti
spill
adjac
interstitium
endotheli
eosinophil
absent
adequ
alveol
artifactfre
specimen
lymphocyt
infiltr
may
detect
low
magnif
often
higher
power
studi
need
identifi
infiltr
although
mild
acut
reject
perivascular
infiltr
lymphocyt
still
confin
perivascular
adventitia
without
infiltr
adjac
interstitium
air
space
layer
lymphocyt
surround
vessel
fig
b
addit
perivascular
mononuclear
infiltr
surround
venul
arteriol
frequent
grade
typic
recogniz
low
magnif
infiltr
usual
consist
mixtur
small
round
lymphocyt
activ
lymphocyt
plasmacytoid
lymphocyt
macrophag
eosinophil
cellular
infiltr
compact
loos
subendotheli
infiltr
mononuclear
cell
may
note
associ
hyperplast
regen
chang
endothelium
concurr
lymphocyt
bronchiol
may
seen
venul
arteriol
cuf
easili
recogniz
dens
perivascular
mononuclear
cell
infiltr
commonli
associ
endotheli
fig
eosinophil
even
occasion
neutrophil
common
b
moder
acut
reject
inflammatori
cell
infiltr
extend
adjac
alveolar
septa
associ
type
ii
pneumocyt
hyperplasia
inflammatori
infiltr
also
extend
adjac
airspac
associ
collect
intraalveolar
macrophag
lymphocyt
histolog
featur
acut
lung
injuri
may
becom
appar
form
airspac
fibrin
sever
reject
diffus
perivascular
interstiti
air
space
infiltr
mononuclear
cell
promin
alveolar
pneumocyt
damag
endotheli
fig
may
associ
necrot
intraalveolar
epitheli
cell
hemorrhag
neutrophil
usual
morpholog
evid
acut
lung
injuri
form
organ
pneumonia
fibrin
deposit
hyalin
membran
parenchym
necrosi
infarct
necrot
vascul
may
identifi
howev
featur
evid
surgic
rather
transbronchi
lung
biopsi
note
paradox
diminut
perivascular
infiltr
occur
cell
extend
interalveolar
septa
air
space
admix
macrophag
protocol
surveil
biopsi
lung
allograft
perform
mani
institut
even
though
patient
gener
asymptomat
clinic
stabl
one
studi
show
surveil
biopsi
reveal
acut
cellular
reject
show
featur
minim
reject
mild
reject
moder
reject
recent
prospect
studi
identifi
morpholog
find
acut
cellular
reject
surveil
biopsi
retrospect
studi
b
surveil
biopsi
taken
within
day
transplant
reveal
histolog
find
either
acut
cellular
reject
oblit
bronchiol
biopsi
within
first
day
day
follow
transplant
evid
suggest
acut
cellular
reject
import
risk
factor
develop
bo
inde
studi
demonstr
increas
risk
bo
singl
episod
increas
frequenc
increas
sever
acut
cellular
reject
moreov
patient
multipl
episod
even
minim
acut
cellular
reject
shown
increas
risk
bo
yet
singl
episod
minim
acut
reject
without
recurr
subsequ
progress
higher
grade
identifi
independ
signific
predictor
bo
find
patient
asymptomat
found
acut
cellular
reject
even
minim
acut
cellular
reject
surveil
allograft
biopsi
might
treat
accordingli
howev
sever
center
util
surveil
transbronchi
lung
biopsi
andor
treat
asymptomat
patient
clinic
evid
allograft
dysfunct
prospect
welldesign
clinic
studi
need
provid
evid
support
surveil
transbronchi
lung
biopsi
therapeut
intervent
grade
appli
small
airway
termin
respiratori
bronchiol
bronchi
present
describ
separ
import
mention
patholog
report
whether
small
airway
present
small
airway
identifi
biopsi
obviou
infect
grade
bx
use
r
behind
grade
denot
revis
version
small
airway
appear
unremark
without
evid
bronchiolar
inflamm
lowgrad
inflamm
character
lymphocyt
within
submucosa
bronchiol
fig
lymphocyt
infiltr
infrequ
scatter
form
circumferenti
band
howev
intraepitheli
lymphocyt
infiltr
present
occasion
eosinophil
may
seen
within
submucosa
evid
epitheli
damag
neutrophil
necrosi
ulcer
signific
amount
nuclear
debri
highgrad
small
airway
inflamm
mark
lymphocyt
infiltr
airway
epithelium
airway
wall
mononuclear
cell
submucosa
appear
larger
greater
number
eosinophil
plasmacytoid
cell
seen
fig
addit
evid
epitheli
damag
includ
necrosi
metaplasia
mark
intraepitheli
lymphocyt
infiltr
sever
form
highgrad
airway
inflamm
associ
epitheli
ulcer
fibrinopurul
exud
cellular
debri
neutrophil
import
exclud
infecti
process
especi
number
neutrophil
disproport
high
compar
mononuclear
cell
within
airway
wall
small
airway
might
evalu
sever
reason
includ
lack
small
airway
due
sampl
problem
infect
tangenti
cut
artifact
etc
patient
known
infect
could
caus
lymphocyt
bronchiol
allograft
biopsi
also
classifi
ungrad
small
airway
reject
chronic
airway
reject
restrict
submucos
intralumin
scar
small
airway
includ
termin
respiratori
bronchiol
larg
tissu
section
lung
examin
oblit
bronchiol
may
recogn
panlobar
process
usual
patchi
small
airway
appear
similar
size
accompani
arteri
rag
inner
surfac
fibrosi
present
narrow
small
airway
due
fibrosi
airway
wall
hallmark
chronic
airway
reject
fibrosi
may
eccentr
concentr
type
fibrosi
depend
acut
process
degre
organ
amount
accompani
inflamm
fibrosi
rang
loos
myxoid
granul
tissu
variabl
number
inflammatori
cell
fill
partial
obstruct
airway
lumen
acut
phase
fig
dens
hyalin
collagen
wall
bronchiol
characterist
chronic
phase
fig
metaplast
squamou
cuboid
epithelium
may
overli
bronchiolar
fibrosi
sometim
slitlik
lumen
airway
may
remain
result
confluent
submucos
scar
intralumin
polyp
scar
tissu
may
rather
promin
capillari
suppli
intralumin
fibrot
area
ultim
bronchiolar
lumen
might
entir
occlud
dens
scar
tissu
fig
case
elast
stain
highlight
residu
elast
tissu
vicin
scar
pulmonari
arteri
residu
smooth
muscl
may
indic
small
airway
replac
fibrot
scar
chronic
phase
inflamm
may
minim
absent
usual
scar
process
confin
exclus
respiratori
bronchiol
termin
bronchiol
although
may
occasion
involv
adjac
alveoli
oblit
bronchiol
infrequ
identifi
lung
allograft
transbronchi
biopsi
sensit
morpholog
find
presenc
chronic
reject
recent
studi
seven
convent
transbronchi
biopsi
includ
patient
clinic
known
bo
clinic
equival
morpholog
oblit
bronchiol
fail
reveal
morpholog
find
oblit
bronchiol
although
cryobiopsi
contain
small
airway
nine
cryobiopsi
also
includ
studi
patient
clinic
proven
bo
reveal
oblit
bronchiol
tissu
low
sensit
larg
due
sampl
patchi
natur
therefor
bo
use
reliabl
clinic
assess
chronic
airway
reject
bo
calcul
fev
least
two
consecut
lung
function
test
patient
maximum
fev
posttransplant
despit
low
sensit
transbronchi
biopsi
oblit
bronchiol
specif
morpholog
find
allograft
biopsi
high
rang
therefor
attempt
diagnos
oblit
bronchiol
made
lung
allograft
biopsi
pulmonari
arteri
appear
similar
size
accompani
airway
intima
slender
media
thicken
chronic
vascular
reject
rare
identifi
biopsi
sinc
usual
lack
vessel
suffici
size
wedg
biopsi
explant
autopsi
materi
may
reveal
therefor
accord
ishlt
grade
reject
applic
allograft
transbronchi
biopsi
although
cryobiopsi
contain
higher
number
venul
small
vein
recent
small
studi
differ
found
number
case
possibl
vascular
reject
compar
transbronchi
biopsi
vascular
reject
character
thicken
pulmonari
arteri
often
vein
due
fibrointim
connect
tissu
fig
b
also
thicken
usual
concentr
chronic
vascular
reject
may
patchi
chronic
vascular
reject
usual
start
intim
prolifer
subsequ
intern
elast
lamina
may
becom
fragment
discontinu
occasion
underli
muscular
wall
becom
thin
approxim
half
report
case
concurr
endovascul
observ
process
similar
pulmonari
vein
although
intim
deposit
may
less
cellular
waxi
eosinophil
sclerot
recan
thrombi
may
mimic
chronic
vascular
reject
contrast
heart
allograft
chronic
vascular
reject
lung
transplant
result
graft
loss
howev
patient
develop
pulmonari
hypertens
particularli
bo
infect
mimic
acut
cellular
reject
instanc
viral
infect
particularli
cmv
fig
also
pneumocysti
jirovecii
pneumonia
associ
perivascular
mononuclear
cell
inflamm
mimick
acut
cellular
reject
infect
also
caus
small
airway
inflamm
imit
lymphocyt
bronchiol
mimick
sever
acut
reject
includ
condit
might
present
acut
lung
injuri
diffus
alveolar
damag
condit
includ
infect
drug
toxic
aspir
amr
harvestreperfus
injuri
presenc
perivascular
inflamm
help
establish
diagnosi
reject
howev
perivascular
inflamm
entir
specif
acut
reject
mani
condit
may
simul
mimic
alloreact
lung
injuri
mark
perivascular
andor
peribronchiolar
mononuclear
infiltr
might
also
rais
possibl
posttransplant
lymphoprolif
diseas
ptld
case
appropri
workup
perform
includ
studi
epsteinbarr
viru
ubiquit
ptld
differenti
diagnosi
perivascular
interstiti
infiltr
includ
recurr
primari
diseas
small
airway
reject
perivascular
infiltr
grade
reject
distinguish
bronchiolarassoci
lymphat
tissu
balt
balt
found
vicin
airway
usual
contain
black
anthracot
pigment
present
rather
nodular
collect
chronic
inflammatori
cell
surround
vessel
fig
epitheli
injuri
neutrophil
eosinophil
seen
balt
collect
origin
recogn
kidney
transplant
patient
present
acut
allograft
reject
antidonor
antibodi
poor
prognosi
amr
well
establish
kidney
heart
allograft
lung
transplant
amr
still
evolv
concept
like
explain
acut
chronic
graft
dysfunctionfailur
subset
patient
evid
suggest
amr
occur
due
circul
antibodi
either
preform
pregnanc
blood
transfus
previou
organ
transplant
aris
de
novo
transplant
due
hla
mismatch
furthermor
recent
develop
sensit
specif
solidphas
flow
cytometri
luminexbas
methodolog
allow
accur
detect
antibodi
specif
sensit
recipi
becom
clear
patient
previous
expect
develop
preform
antihla
antibodi
immun
stimul
prior
infect
autoimmun
may
also
contribut
develop
antibodi
patient
identifi
risk
factor
overal
preexist
de
novo
antibodi
react
donor
antigen
lead
immedi
graft
loss
hyperacut
reject
acceler
humor
reject
andor
bo
addit
recent
studi
consist
demonstr
increas
incid
acut
reject
threefold
increas
one
studi
persist
reject
increas
bo
wors
overal
surviv
patient
antihla
antibodi
effect
seen
pretranspl
hla
sensit
develop
de
novo
antihla
donorspecif
antibodi
transplant
lung
transplant
recipi
presensit
hla
antigen
even
though
unaccept
antigen
avoid
virtual
crossmatch
patient
posit
pretranspl
pra
higher
risk
posttranspl
complic
posttranspl
pra
stay
stabl
increas
via
gener
either
donorspecif
nondonorspecif
antihla
antibodi
similarli
patient
neg
pra
screen
test
transplant
develop
de
novo
nondonorspecif
donorspecif
antihla
antibodi
transplant
mechan
antibodi
promot
lung
allograft
injuri
remain
poorli
understood
antibodi
bind
allohla
endotheli
epitheli
target
lung
allograft
activ
complement
cascad
complement
deposit
lead
endotheli
cell
injuri
product
proinflammatori
molecul
recruit
inflammatori
cell
complementindepend
antibodymedi
mechan
also
induc
endotheli
cell
activ
without
cell
injuri
lead
increas
gene
express
subsequ
prolifer
furthermor
demonstr
vitro
studi
antihla
antibodi
caus
prolifer
airway
epitheli
cell
well
produc
fibroblaststimul
growth
factor
potenti
contribut
gener
oblit
bronchiol
although
diagnosi
amr
lung
allograft
biopsi
remain
challeng
tripl
test
criteria
met
graft
dysfunct
posit
panel
reactiv
antibodi
evid
complement
deposit
graft
diseas
lifethreaten
prognosi
poor
although
optim
treatment
amr
lung
current
known
due
lack
clinic
trial
treatment
typic
compris
plasmapheresi
possibl
intraven
immunoglobulin
ivig
medic
rituximab
bortezomib
among
other
associ
histopatholog
clinic
paramet
subject
intens
investig
deposit
complement
complement
split
product
capillari
endothelium
suggest
surrog
marker
amr
heart
kidney
pancrea
transplant
howev
role
deposit
diagnosi
amr
lung
allograft
still
unclear
moreov
reproduc
deposit
allograft
lung
tbbx
problemat
even
among
pathologist
routin
evalu
lung
allograft
biopsi
furthermor
current
specif
sensit
morpholog
featur
amr
lung
allograft
although
featur
commonli
identifi
patient
emerg
recent
studi
studi
attempt
evalu
immunoglobulin
ig
complement
deposit
subendotheli
space
septal
capillari
deposit
ig
complement
product
describ
associ
antihla
antibodi
well
allograft
dysfunct
bo
howev
except
institut
studi
gener
implement
workup
lung
transplant
biopsi
possibl
amr
one
reason
difficulti
lung
rel
high
background
encount
immunohistochem
well
immunofluoresc
studi
often
bind
vascular
elast
lamina
show
nonspecif
bind
intracapillari
serum
stain
commonli
focal
therefor
sensit
specif
establish
linear
continu
lumin
endotheli
stain
capillari
arteriol
andor
venul
interpret
posit
addit
specif
amr
also
seen
infect
harvestreperfus
injuri
process
associ
complement
activ
gener
concept
specif
histopatholog
featur
associ
amr
remain
controversi
lung
transplant
ishlt
revis
consensu
classif
propos
histopatholog
featur
might
specif
amr
lack
specif
histolog
find
amr
multidisciplinari
approach
diagnosi
recommend
includ
follow
presenc
circul
antibodi
hla
antibodi
antiendotheli
antiepitheli
antibodi
focal
diffus
deposit
fig
histolog
featur
acut
lung
injuri
hemorrhag
diffus
alveolar
damag
capillari
injuri
associ
neutrophil
nuclear
debri
ie
capillar
clinic
sign
graft
dysfunct
patholog
council
ishlt
publish
find
summari
statement
recommend
patholog
evalu
amr
report
includ
suggest
protocol
biopsi
serolog
evalu
donorspecif
antibodi
dsa
near
time
biopsi
addit
statement
includ
recommend
histopatholog
pattern
amr
fig
indic
immunohistochem
immunofluoresc
studi
elucid
find
amr
box
morpholog
featur
confirm
consensu
report
ishlt
consensu
report
confirm
need
multidisciplinari
approach
establish
diagnosi
amr
lung
integr
clinic
present
avail
immunolog
patholog
diagnost
tool
amr
stage
also
propos
tabl
recent
wallac
colleagu
report
find
banff
studi
patholog
allograft
lung
dsa
nine
experienc
lung
transplant
pathologist
multipl
institut
perform
digit
slide
interpret
studi
transbronchi
biopsi
specimen
patient
known
antibodi
statu
establish
within
day
biopsi
neg
infecti
workup
studi
demonstr
biopsi
patient
dsa
commonli
show
morpholog
featur
acut
lung
injuri
without
diffus
alveolar
damag
biopsi
patient
nondsa
circul
antibodi
endotheli
common
patient
dsa
patient
without
circul
antibodi
howev
differ
occurr
endotheli
biopsi
patient
circul
nondsa
vs
dsa
nondsa
vs
circul
antibodi
specimen
associ
dsa
signific
higher
frequenc
capillari
inflamm
includ
neutrophil
margin
increas
neutrophil
capillar
karyorrhexi
patient
nondsa
circul
antibodi
stain
posit
less
capillari
biopsi
capillari
biopsi
differ
group
biopsi
stain
biopsi
dsa
often
capillari
stain
biopsi
without
circul
antibodi
signific
differ
identifi
hla
class
dsa
evalu
patholog
find
taken
togeth
studi
identifi
capillari
inflamm
acut
lung
injuri
endotheli
morpholog
featur
lung
allograft
biopsi
correl
presenc
circul
dsa
howev
none
histopatholog
featur
specif
patient
dsa
morpholog
find
acut
lung
injuri
diffus
alveolar
damag
highest
odd
ratio
presenc
circul
dsa
studi
also
caution
use
immunohistochem
stain
diagnosi
amr
lung
allograft
infrequ
diffus
posit
although
studi
show
morpholog
featur
correl
presenc
circul
dsa
therefor
might
histopatholog
marker
least
suggest
possibl
amr
reproduc
morpholog
featur
quit
problemat
even
among
experienc
lung
transplant
pathologist
fact
interobserv
reproduc
kappa
valu
rang
indic
less
chanc
moder
agreement
lowest
agreement
note
suspicion
aspir
median
kappa
highest
acut
cellular
reject
alveolar
hemosiderosi
stain
median
kappa
although
definit
diagnosi
amr
seem
elud
patholog
interpret
current
time
fulli
contextu
clinic
environ
find
biopsi
specimen
may
aid
clinician
make
reason
diagnosi
amr
relev
clinic
serolog
featur
present
propos
tripl
test
clinic
featur
serolog
evid
dsa
patholog
find
support
amr
includ
capillari
inflamm
acut
lung
injuri
without
diffus
alveolar
damag
endotheli
may
current
best
guid
diagnosi
amr
ihslt
recommend
time
regard
coexist
amr
acut
reject
clearli
occur
hyperacut
reject
sever
form
amr
mediat
preexist
antibodi
abo
blood
group
hla
class
ii
antigen
graft
vascular
endotheli
cell
reject
occur
within
minut
hour
transplant
organ
begin
perfus
form
amr
preexist
antibodi
result
previou
pregnanc
blood
transfus
previou
transplant
bind
donor
antigen
provok
complement
cytokin
activ
result
endotheli
cell
damag
platelet
activ
subsequ
vascular
thrombosi
graft
destruct
outcom
commonli
fatal
hyperacut
reject
lung
edemat
cyanot
heavi
firm
consist
lack
crepit
show
red
hepat
cut
surfac
reveal
patchi
poorli
defin
area
hemorrhag
consolid
anastomos
intact
typic
wide
patent
histolog
alveolar
hemorrhag
platelet
fibrin
thrombi
neutrophil
infiltr
necrosi
vessel
wall
diffus
alveolar
damag
observ
deposit
describ
although
hyperacut
reject
wellknown
complic
kidney
heart
transplant
lung
transplant
appear
rather
rare
eight
case
report
six
patient
die
within
h
day
transplant
two
patient
surviv
one
two
patient
treat
plasmapheresi
antithymocyt
globulin
cyclophosphamid
immedi
hyperacut
reject
diagnos
patient
highli
presensit
underw
doubl
lung
transplant
patient
treat
multipl
plasma
exchang
intraven
immunoglobulin
preand
posttransplant
togeth
posttranspl
rituximab
bortezomib
later
antibodi
eculizumab
although
pretranspl
panel
reactiv
antibodi
pra
neg
four
eight
report
patient
crossmatch
posit
report
case
collect
although
hyperacut
reject
rare
lung
transplant
one
keep
reaction
mind
given
falseneg
pra
may
occur
pretransplant
crossmatch
often
possibl
least
five
piec
wellexpand
alveol
parenchyma
requir
adequ
evalu
transbronchi
lung
allograft
biopsi
specimen
acut
reject
lrsg
specimen
requir
base
uniform
opinion
consensu
meet
ensur
minimum
number
requir
piec
alveol
lung
parenchyma
avail
patholog
review
recommend
bronchoscopist
need
take
five
piec
even
piec
might
necessari
provid
small
airway
review
interestingli
prospect
singleoper
studi
scott
colleagu
includ
transbronchi
allograft
biopsi
sampl
per
procedur
mean
sampl
per
procedur
taken
lobe
lobe
lingula
lung
heartlung
transplant
singl
lung
transplant
recipi
reveal
sensit
specif
identif
reject
histopatholog
studi
estim
sampl
per
procedur
need
confid
find
reject
therefor
falseneg
result
due
patchi
distribut
acut
reject
like
uncommon
absenc
histolog
immunophenotyp
featur
acut
reject
antibodymedi
reject
requir
clinicopatholog
correl
neg
biopsi
necessari
rule
reject
furthermor
bronchoscopist
familiar
imag
studi
especi
high
resolut
comput
tomographi
studi
avail
aim
sampl
radiolog
abnorm
bronchopulmonari
segment
imag
recent
perform
result
normal
sampl
obtain
differ
lobe
tri
minim
sampl
error
specimen
gentli
agit
formalin
open
alveoli
current
recommend
cryobiopsi
recent
studi
use
cryobiopsi
evalu
reject
lung
allograft
median
three
piec
provid
twice
mani
alveoli
small
airway
median
ten
piec
convent
forcep
biopsi
ishlt
recommend
minimum
three
level
paraffin
block
hematoxylin
eosin
h
e
stain
histolog
examin
addit
connect
tissu
stain
trichrom
verhoeffvan
gieson
vvg
stain
recommend
evalu
airway
presenc
submucos
fibrosi
vessel
graft
vascular
diseas
stain
microorgan
includ
gomorigrocott
methenamin
silver
stain
gm
acid
fast
bacilli
afb
may
ad
silver
stain
routin
perform
lung
allograft
biopsi
institut
current
mandat
lrsg
mani
microbiolog
serolog
molecular
techniqu
avail
use
identifi
infect
patient
bal
may
perform
time
biopsi
use
exclus
infect
current
clinic
role
diagnosi
acut
reject
transbronchi
allograft
biopsi
current
gold
standard
evalu
graft
cellular
reject
exclud
clinic
mimick
lung
transplant
patient
review
transbronchi
biopsi
materi
patient
attent
must
paid
featur
reject
also
morpholog
mimick
especi
infect
ptld
abnorm
drug
effect
diagnosi
acut
cellular
reject
render
infecti
process
exclud
use
stain
microorgan
clinic
test
includ
cultur
bal
andor
tissu
serolog
studi
identifi
histopatholog
immunophenotyp
featur
amr
evolv
current
specif
morpholog
find
clinic
serolog
correl
requir
diagnosi
prospect
welldesign
longterm
studi
longitudin
data
therapeut
intervent
acr
histopatholog
total
asymptomat
patient
physiolog
hrct
evid
allograft
dysfunct
need
determin
clinic
signific
relev
intervent
